News Column

Information concerning Bactiguard’s corporate bonds

May 22, 2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. In a press release issued today, the Board of Directors of Bactiguard Holding AB (publ) (“Bactiguard” or “the Company”) confirmed its intention to proceed with an IPO of Bactiguard on NASDAQ OMX Stockholm. The IPO is expected to take place in late June 2014.

Prior to the planned IPO, holders of Bactiguard’s corporate bonds will be contacted individually by Bactiguard and offered* the option to offset their bonds against Bactiguard shares, contingent upon completion of the IPO. The outcome of the set-off issue will be announced in conjunction with the start of the acceptance period for the general public.

The offer involves offsetting bondholders’ nominal bond claims against Bactiguard, plus interest accrued as of the decision date for the set -off issue, against Bactiguard B-shares at a price corresponding to the IPO share price in the Bactiguard IPO with the application of a 5 per cent premium to the nominal amount of the bond claims. There will also be an opportunity to sell offset shares in conjunction with the offer to the general public. The IPO share price that forms the basis for the offset offer will not exceed SEK 50 per share.

Swedbank has been appointed Lead Manager and Sole Bookrunner and ABG Sundal Collier have been appointed Co-Lead Managers in connection with the intended IPO. Cederquist is legal advisor.

*The offset offer is directed solely to those receiving the offer from the Company in letter format (fewer than 150 people).


Bactiguard Holding AB (publ) is required to disclose the above

information under the provisions of the Securities Market Act and/or the

Swedish Financial Instruments Trading Act. The information was submitted

for publication at 8:15 AM CET on 23 May 2014.

Fredrik JÄrrsten - CFO ( +46 725 500 089

Cecilia EdstrÖm - KommunikationsdirektÖr +46 722 262 328 Bactiguard Bactiguard is a Swedish medtech company with a business concept of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company’s patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of coated catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the EU, Middle East, Asia and South America. The company reported  sales of approximately SEK 130 million in 2013, has 60 employees, headquarters in Stockholm and production facilities in Markaryd and Malaysia.

This information was brought to you by Cision,c9590373

The following files are available for download:

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Cision

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters